Study on the construction of the quality evaluation system of Chinese drug GMP inspectionHU Shi-gao, WU Zhi-ang209-215
Key points on complement of continuous supply for national drug reference standardsGAO Zhi-feng, LUO Chen, LIU Ming-li, ZHAO Zong-ge, WANG Qing, SUN Hui-min216-220
Regulatory status and considerations on nitrosamine impurities in human drugsWANG Gong-fu, TANG Jia221-228
Regulatory practice and enlightenment of foreign drug frontier technologyYU Ming-li, XIA Wen-jing, JIANG Xiao-meng, WEN Bao-shu229-240
Research progress on the effect of glycosylation on vaccine immunogenicityWANG Her-ru, WU Ye-hong, HE Peng, HU Zhong-yu241-246
Research progress of long-acting growth hormone preparationsLIU Qing-yang, ZHANG Juan, HOU Zi-jing, KANG Chen, LIU Xin, ZHANG Bo, TANG Yan247-254
Clinical application advantages and prospects of innovative powder-liquid dual-chamber bagsLI He, BAI Qiu-ju, ZHANG Xiu-li, ZHANG Yu-jia, YANG Guo-hong, ZHENG Wen-sheng255-260
Prediction of the developing trend of decentralized clinical trials in China based on GM(1,1)modelZHANG Jing, JIA Zheng, FU Shu-yong, XING Hua261-269
Application of annotated case report form based on study data tabulation model in domestic clinical trialsTAN Lei, CHAO Jian-qian270-273
Investigation and analysis of the awareness degree of clinical trial liability insurance for investigator-initiated trialsCAO Ye, LIN Zhen, LI Bin-bin, LIU Ya-qing, FU Zhong274-278